

Risk insights: Life sciences

A successful risk management programme needs to be all-encompassing and not focused solely on prescriptive regulatory requirements.

The life sciences industry continues to become ever more dynamic and complex. Comprising bio-technology, pharmaceutical and medical devices as well as other industry sub sectors, this industry remains highly regulated, highly capital intensive and highly reliant on data quality.

Consolidation in the industry continues with strategic acquisitions and alliances happening most notably to strengthen and improve product pipeline, R&D capabilities and in certain cases secure innovative technologies.

These characteristics support the risk management challenge facing life science organisations - that being; the oversight, active management, monitoring and reporting of operational risk. Operational risk in these organisations has become sizeable and multi layered, with many grappling with an enterprise wide view of risk across their organisations. There is a genuine need to move away from an outdated and siloed approach to risk management, largely driven by a heavy regulatory and compliance agenda, if these organisations are to best protect themselves from the growing levels of operational risk that are being experienced.

To optimally manage enterprise risk and most especially operational risk, such organisations need to have robust governance, risk and internal control mechanisms in place. The transparency and integrity of these arrangements can't be overstated most especially given lengthy product lifecycles that have to be financed and resourced and the expectations of the wide reaching stakeholder groups that exist within this industry.

In the context of operational risk specifically, the increased usage of Contract Management Organisations (CMOs) in the research, validation, production, distribution, marketing and selling of products has shone a light on the acute need for truly integrated Third Party Risk Management (TPRM) programmes that are fit for purpose and not only deliver greater competitiveness but also provide enhanced data transparency and support end to end risk management practices.



Life sciences:
Illustrative risks

- Strategic**
Business model, niche biotech players, M&A, joint ventures and strategic partnerships.
- Financial**
Capital/funding, liquidity, credit, foreign exchange, Revenue recognition, chargebacks and rebates.
- Operational**
Governance, culture, talent, third party and outsourcing, supply chain, product risk (conduct, quality and liability), technology, cyber, digitalisation, innovation, data management, R&D and intellectual property, business continuity management, DRP, operational resilience, fraud, CSR.
- Regulatory & compliance**
GMP, FCPA, SOX 404, GDPR, REMS, litigation, taxation.
- Market**
Market volatility, emerging markets, disruptive technologies.

The use of third parties and TPRM is crucial to the Life Sciences industry and its future growth and competitiveness but such programs require a clear and distinct strategy, defined ownership, a transparent and communicated operating model, optimised processes and investment in technology and innovation tools, if they are to contribute value strategically and commercially.

The pandemic has further highlighted the need for an integrated approach to risk management within the Life Sciences sector. Operational risk has been exacerbated by matters such as crisis management, BCM and supply chain contingency planning in many instances and the level of inter-dependencies that exist in such complex organisations. Adequate scenario planning and testing is essential so as to have holistic 'go to' plans in place to address people process, property and technology contingency during times of crisis and in turn work to minimise the crystallisation of operational risk.

How can we help?

Many of our team are senior risk professionals from the life sciences and other regulated sectors. They have held key risk, compliance and internal audit roles in such organisations and bring a wealth of real life experience to the table.

Our Life Sciences specialist sector group and business risk consulting team work together to offer the unique mix of industry subject matter expertise and best fit governance, risk and control solutions to meet your needs. We have helped our life science clients navigate:

- risk assessments and frameworks;
- Third Party Risk Management (TPRM);
- Business Continuity Management (BCM);
- IT/cyber security reviews;
- contract/rebate assurance;
- supply chain third party audits;
- SOX, FCPA, ethics, quality and compliance audits.

Contact

If you would like more information on our risk consulting services please contact a member of our dedicated team.



Sara McAllister
Head of
Business Risk Services
T +353 (0)1 680 5716
E sara.mcallister@ie.gt.com



Onatkut Varis
IT Associate Director,
Business Risk Services
T +353 (0)1 680 5905
E onatkut.varis@ie.gt.com



Channele Da Silva
Risk Manager,
Business Risk Services
T +353 (0)1 680 5852
E channele.dasilva@ie.gt.com

Offices in Dublin, Belfast, Cork, Galway, Kildare, Limerick and Longford.



grantthornton.ie



@GrantThorntonIE



Grant Thornton Ireland



grantthornton.ie

© 2021 Grant Thornton Ireland. All rights reserved. Authorised by Chartered Accountants Ireland ("CAI") to carry on investment business. 'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton International Ltd (GTIL) and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate, one another and are not liable for one another's acts or omissions. This publication has been prepared only as a guide. No responsibility can be accepted by us for loss occasioned to any person acting or refraining from acting as a result of any material in this publication.



Case study

Regulatory and product quality focus.
No holistic risk management practices in place.

Situation

An international pharmaceutical business needed a holistic assessment of its risk universe and its risk management practices in its domestic business in order to determine how resources would be best used and spent in the management of risk going forward.

Solution

We conducted an enterprise wide risk assessment across the business to identify, quantify and assess risks on a function by function basis and the mechanisms in place to manage same. This assessment was coupled with management risk training and methodology workshops.

Outcome

A comprehensive risk register that provided a single view of risk across the business for the board and management to use as a starting point to implement a risk management improvement project.

A defined risk appetite and clear and standardised approach to risk assessment common to all parts of the business.

A prioritised list of risks requiring immediate attention, most notably highlighting the need for a centralised third party risk management function and framework.